What is the generic name of Mekinist?

The generic name is trametinib, a MEK1/MEK2 inhibitor.

Who manufactures Mekinist?

Mekinist is manufactured by Novartis.

What type of drug is Mekinist?

It is a targeted therapy that blocks MEK1/MEK2 proteins in the MAPK signaling pathway, slowing tumor growth in BRAF V600-mutant cancers.

Is Mekinist FDA-approved?

Yes, Mekinist is FDA-approved for BRAF V600-mutant melanoma, non-small cell lung cancer, and anaplastic thyroid cancer, typically in combination with dabrafenib (Tafinlar).

What is Mekinist used for?

Mekinist is used to treat unresectable or metastatic melanoma, adjuvant Stage III melanoma, advanced NSCLC, and anaplastic thyroid cancer, all with a BRAF V600 mutation.

What is the dosage form of Mekinist?

Mekinist is supplied as oral tablets in 0.5 mg and 2 mg strengths.

What is the typical dosing schedule?

The standard dose is 2 mg orally once daily, taken on an empty stomach, alone or combined with dabrafenib.

What are the common side effects of Mekinist?

Common side effects include rash, diarrhea, fatigue, and peripheral edema. Serious risks include cardiomyopathy, ocular toxicity, and interstitial lung disease.

How can I import Mekinist to India?

Mekinist can be imported through a regulated Named Patient Program with a valid prescription and BRAF mutation test confirmation, supported by NPP's documentation and cold-chain logistics process.

Why should I use a reliable supplier for Mekinist?

A verified supplier ensures product authenticity, proper cold-chain handling, and regulatory compliance, which is critical for this temperature-sensitive oncology therapy.

What does Mekinist cost in India?

Cost depends on dosage, quantity, and import logistics. Contact NPP for a transparent, itemized quotation.

Can patients from SAARC or Gulf countries access Mekinist through NPP?

Yes, NPP supports patients from SAARC and Gulf countries through the same regulated import pathway, subject to local regulatory requirements.

How should Mekinist be stored?

Store refrigerated at 2°C to 8°C, protected from moisture and light, in the original carton.

Call Us for Support

+91 9654860915

Google Reviews

4.8

Cities We Serve How to Order Online Order

About Us Named Patient Program

Cities We Serve Contact Us

Sourced directly from the authorized manufacturer network to ensure authenticity and quality.

Ready to proceed? Order Mekinist on our secure patient portal to submit your prescription, upload documents and track your approval status.

Mekinist

Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.

Medicine Name: Mekinist

Generic Name (API): Trametinib

Dosage Form & Strength: 0.5 mg, 2 mg

Route: Oral

Drug Class: MEK1/MEK2 inhibitor

Manufacturer / Innovator:

Novartis

Regulatory Approval:

FDA (US)
EMA (Europe)
HC (Canada)

Prescribing Information Resources

Family enjoying life with Named Patient Program access

Your Trustworthy Partner For Named Patient Program

Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.

GDP Compliant View Certificate

Licensed Wholesale distributor View Certificate

Understanding Mekinist (Trametinib) and Its Medical Uses

Mekinist (trametinib) is an oral targeted therapy that inhibits MEK1 and MEK2, key proteins in the MAPK signaling pathway that drives tumor growth in cancers with a BRAF V600 mutation. It is often used together with Tafinlar (dabrafenib) for enhanced effect.

Approved Indications

Mekinist is FDA-approved, as monotherapy or in combination with dabrafenib, for adult patients with unresectable or metastatic melanoma carrying a BRAF V600 mutation. In combination with dabrafenib, it is also approved for adjuvant treatment of resected Stage III BRAF V600-mutant melanoma, for BRAF V600-mutant advanced non-small cell lung cancer, and for BRAF V600E-mutant anaplastic thyroid cancer.

How It Works

By blocking MEK1/MEK2, trametinib interrupts the MAPK signaling cascade downstream of mutated BRAF, slowing or halting tumor cell growth.

Dosing

The recommended dose is 2 mg orally once daily, taken at least 1 hour before or 2 hours after a meal, either alone or in combination with dabrafenib (150 mg twice daily), as determined by the treating oncologist.

Warnings and Precautions for Mekinist

Mekinist requires monitoring for several serious adverse effects, particularly when combined with dabrafenib.

Cardiomyopathy

Assess left ventricular ejection fraction before starting, at one month, and periodically during treatment.

Ocular Toxicity

Retinal vein occlusion and retinal pigment epithelial detachment have been reported. Perform ophthalmologic exams periodically and for any visual disturbances.

Interstitial Lung Disease / Pneumonitis

Monitor for new or worsening pulmonary symptoms; withhold or discontinue as needed.

Serious Skin Toxicity

Rash and other skin reactions can occur, including severe cases; monitor closely, especially in combination therapy.

Hemorrhage

Increased bleeding risk, particularly when combined with dabrafenib. Monitor for signs of bleeding.

Hyperglycemia

Monitor blood glucose, particularly in diabetic patients.

Embryo-Fetal Toxicity

Mekinist can cause fetal harm. Advise effective contraception during treatment and for a defined period after the final dose.

Cardiac and ophthalmologic monitoring is required throughout treatment.
Report any new visual changes, breathing difficulty, or skin reactions promptly.
Dosing and monitoring intervals differ between monotherapy and combination therapy — follow the treating oncologist's regimen.

How to Access Mekinist in India: A 6-Step Process

Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.

Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.

Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.

Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.

Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant, cold-chain conditions to maintain product integrity.

Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.

Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.

Documentation and Availability of Mekinist

Mekinist (trametinib) is manufactured by Novartis and is frequently prescribed together with Tafinlar (dabrafenib) as a combination regimen for BRAF V600-mutant cancers.

Documentation Required

Import of Mekinist through a Named Patient Program requires a valid prescription from the treating oncologist, confirmation of BRAF V600 mutation status via an FDA-approved test, and supporting clinical documentation as required by Indian regulatory authorities.

Sourcing

NPP sources Mekinist directly from Novartis's authorized supply chain to ensure product authenticity and regulatory compliance.

Sourcing and Delivery of Mekinist

Mekinist is sourced through verified, GDP-compliant, cold-chain channels from Novartis's authorized supply chain to ensure authenticity and quality.

Storage Requirements

Mekinist tablets should be stored refrigerated at 2°C to 8°C, protected from moisture and light, and kept in the original carton.

Delivery Process

Once sourced, Mekinist is packed and transported under continuous cold-chain conditions to preserve product integrity throughout the import process, with tracking and updates provided at each stage of delivery to the patient or treating hospital in India.

Availability of Mekinist Across Major Cities in India

Patients across India can access Mekinist through NPP's regulated import pathway, with oncology specialists in major cities supporting the treatment process.